Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck VP & Chief Licensing Officer Barbara Yanni: An Interview With “The Pink Sheet” DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck is bolstering its pipeline through acquisitions and licensing deals, many in biotech. The drug maker evaluates 6,000 opportunities per year and signed 44 transactions in 2005.

You may also be interested in...



Merck Finds Licensing More Palatable Than Large Acquisitions

During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.

Merck Finds Licensing More Palatable Than Large Acquisitions

During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.

Big Pharma Is Paying More, Earlier For Biotechs

Acquisition deals become more expensive as pharmas compete to fill pipelines, execs say at BIO meeting in Boston.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel